journal article·2026-03Open access

Evolution of Prime Editing: Enhancing Efficiency and Expanding Capacity

Jihyeon Yu, Ju‐Chan Park, Heesoo Uhm, Yong‐Woo Kim, Hyeon Woo Im, Sangsu Bae

Advanced Science· Volume 13· Issue 16

Abstract

ABSTRACT Genetic mutations cause approximately 80% of rare human diseases, highlighting the urgent need for precise genome editing. Since clustered regularly interspaced short palindromic repeat (CRISPR)‐CRISPR‐associated 9 (Cas9) nucleases were first used for genome editing in 2012, genome editing technologies have rapidly advanced. Base editors, derived from the CRISPR‐Cas system, were developed to introduce specific point mutations without requiring DNA double‐strand breaks, and subsequently, prime editing (PE) technology was created to enable insertions, deletions, and all types of point mutations. The precision and versatility of PE make it a promising tool for clinical applications. However, PE has potential limitations, including low editing efficiency and limited capacity for large‐scale manipulation. To overcome these limitations, research has been continuously conducted to improve PE efficiency and expand its capabilities. Therefore, this review aims to highlight current efforts and future directions for developing and improving PE‐related tools.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: CRISPR and Genetic Engineering · Innovative Microfluidic and Catalytic Techniques Innovation · Biosensors and Analytical Detection

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Biomedical Convergence Engineering Pusan National University Yangsan Republic of Korea

Genomic Medicine Institute Seoul National University College of Medicine Seoul Republic of Korea

Harvard Medical School Boston Massachusetts USA

Department of Biomedical Sciences Seoul National University College of Medicine Seoul Republic of Korea

Cancer Research Institute Seoul National University College of Medicine Seoul Republic of Korea

Institute of Molecular Biology and Genetics Seoul National University Seoul Republic of Korea

Funding

Ministry of Food and Drug Safety · National Research Foundation of Korea

References (98)

Show source-provided references
1. 10.1146/annurev‐biochem‐072911‐17231510.1146/annurev‐biochem‐072911‐172315 ↗
2. 10.1038/nature1538610.1038/nature15386 ↗
3. 10.1126/science.122582910.1126/science.1225829 ↗
4. 10.1038/nbt.250710.1038/nbt.2507 ↗
5. 10.1126/science.123114310.1126/science.1231143 ↗
6. 10.1038/cr.2007.11110.1038/cr.2007.111 ↗
7. 10.1038/s41551‐024‐01277‐510.1038/s41551‐024‐01277‐5 ↗
8. 10.1038/s41586‐018‐0380‐z10.1038/s41586‐018‐0380‐z ↗
9. 10.1038/nbt.419210.1038/nbt.4192 ↗
10. 10.1038/s41467‐022‐30480‐810.1038/s41467‐022‐30480‐8 ↗
11. 10.1038/nbt.311710.1038/nbt.3117 ↗
12. 10.1038/s41588‐021‐00838‐710.1038/s41588‐021‐00838‐7 ↗
13. 10.1126/science.aba736510.1126/science.aba7365 ↗
14. 10.1126/science.adg322410.1126/science.adg3224 ↗
15. 10.1038/s41591‐018‐0049‐z10.1038/s41591‐018‐0049‐z ↗
16. 10.1038/s41588‐020‐0623‐410.1038/s41588‐020‐0623‐4 ↗
17. 10.1016/j.xcrm.2025.10215710.1016/j.xcrm.2025.102157 ↗
18. 10.1038/nature1794610.1038/nature17946 ↗
19. 10.1038/nature2464410.1038/nature24644 ↗
20. 10.1093/nar/gkv122210.1093/nar/gkv1222 ↗
21. 10.15283/ijsc2217110.15283/ijsc22171 ↗
22. 10.1093/nar/gkaf28110.1093/nar/gkaf281 ↗
23. 10.1038/s41586‐019‐1711‐410.1038/s41586‐019‐1711‐4 ↗
24. 10.1016/j.cell.2021.09.01810.1016/j.cell.2021.09.018 ↗
25. 10.1038/s41587‐024‐02405‐x10.1038/s41587‐024‐02405‐x ↗
26. 10.1038/s41596‐020‐00410‐310.1038/s41596‐020‐00410‐3 ↗
27. 10.1016/j.cell.2023.07.03910.1016/j.cell.2023.07.039 ↗
28. 10.1038/s41467‐025‐60495‐w10.1038/s41467‐025‐60495‐w ↗
29. 10.1126/science.ads001810.1126/science.ads0018 ↗
30. 10.1038/s41587‐022‐01255‐910.1038/s41587‐022‐01255‐9 ↗
31. 10.1038/s41556‐019‐0425‐z10.1038/s41556‐019‐0425‐z ↗
32. 10.1016/j.cobme.2023.10050610.1016/j.cobme.2023.100506 ↗
33. 10.1038/s41467‐022‐28442‐110.1038/s41467‐022‐28442‐1 ↗
34. 10.1016/j.omtn.2023.05.01510.1016/j.omtn.2023.05.015 ↗
35. 10.1016/j.cell.2025.07.01010.1016/j.cell.2025.07.010 ↗
36. 10.1038/s41586‐023‐06415‐810.1038/s41586‐023‐06415‐8 ↗
37. 10.1038/s41586‐025‐09537‐310.1038/s41586‐025‐09537‐3 ↗
38. 10.1186/s13059‐021‐02389‐w10.1186/s13059‐021‐02389‐w ↗
39. 10.1016/j.omtn.2022.05.03610.1016/j.omtn.2022.05.036 ↗
40. 10.2174/157340211266616030210251510.2174/1573402112666160302102515 ↗
41. 10.1038/s41467‐023‐35919‐010.1038/s41467‐023‐35919‐0 ↗
42. 10.1016/j.cell.2024.03.02010.1016/j.cell.2024.03.020 ↗
43. 10.1038/s41467‐021‐25928‐210.1038/s41467‐021‐25928‐2 ↗
44. 10.1038/s41587‐022‐01254‐w10.1038/s41587‐022‐01254‐w ↗
45. 10.1038/s41587‐021‐01039‐710.1038/s41587‐021‐01039‐7 ↗
46. 10.1038/s41467‐022‐29507‐x10.1038/s41467‐022‐29507‐x ↗
47. 10.1093/jmcb/mjac02210.1093/jmcb/mjac022 ↗
48. 10.1093/procel/pwac01410.1093/procel/pwac014 ↗
49. 10.1038/s41586‐024‐07259‐610.1038/s41586‐024‐07259‐6 ↗
50. 10.1146/annurev.biochem.71.090501.15000310.1146/annurev.biochem.71.090501.150003 ↗
51. 10.1038/s41587‐023‐02095‐x10.1038/s41587‐023‐02095‐x ↗
52. 10.1016/j.ijbiomac.2024.13085310.1016/j.ijbiomac.2024.130853 ↗
53. 10.1186/s12943‐020‐01246‐x10.1186/s12943‐020‐01246‐x ↗
54. 10.1038/s41467‐025‐59120‐710.1038/s41467‐025‐59120‐7 ↗
55. 10.1038/s41929‐025‐01406‐610.1038/s41929‐025‐01406‐6 ↗
56. 10.1074/jbc.M114.56462510.1074/jbc.M114.564625 ↗
57. 10.1038/nature2056510.1038/nature20565 ↗
58. 10.1038/s41587‐021‐00868‐w10.1038/s41587‐021‐00868‐w ↗
59. 10.1038/s41587‐021‐01133‐w10.1038/s41587‐021‐01133‐w ↗
60. 10.1038/s41587‐021‐01025‐z10.1038/s41587‐021‐01025‐z ↗
61. 10.1038/s41589‐021‐00889‐110.1038/s41589‐021‐00889‐1 ↗
62. 10.1038/s41592‐022‐01399‐110.1038/s41592‐022‐01399‐1 ↗
63. 10.1038/s41587‐021‐01026‐y10.1038/s41587‐021‐01026‐y ↗
64. 10.1093/nar/gkac50610.1093/nar/gkac506 ↗
65. 10.1016/j.ymthe.2022.09.00810.1016/j.ymthe.2022.09.008 ↗
66. 10.1038/s41467‐023‐39137‐610.1038/s41467‐023‐39137‐6 ↗
67. 10.1016/j.cell.2024.05.05610.1016/j.cell.2024.05.056 ↗
68. 10.1038/s41589‐025‐02033‐910.1038/s41589‐025‐02033‐9 ↗
69. 10.1038/s41587‐022‐01527‐410.1038/s41587‐022‐01527‐4 ↗
70. 10.1101/2025.09.14.67613410.1101/2025.09.14.676134 ↗
71. 10.1101/2025.06.16.65992610.1101/2025.06.16.659926 ↗
72. 10.1101/2025.06.16.65997810.1101/2025.06.16.659978 ↗
73. 10.1016/j.cell.2020.10.02510.1016/j.cell.2020.10.025 ↗
74. 10.1093/nar/gkaa76410.1093/nar/gkaa764 ↗
75. 10.1038/s41467‐022‐35743‐y10.1038/s41467‐022‐35743‐y ↗
76. 10.1038/s41592‐023‐01859‐210.1038/s41592‐023‐01859‐2 ↗
77. 10.1093/nar/gkab129510.1093/nar/gkab1295 ↗
78. 10.1038/s41467‐020‐19136‐710.1038/s41467‐020‐19136‐7 ↗
79. 10.1126/science.aav997310.1126/science.aav9973 ↗
80. 10.1038/s41587‐020‐0677‐y10.1038/s41587‐020‐0677‐y ↗
81. 10.1038/s41587‐022‐01613‐710.1038/s41587‐022‐01613‐7 ↗
82. 10.1038/s41587‐024‐02268‐210.1038/s41587‐024‐02268‐2 ↗
83. 10.1016/j.cell.2023.03.03410.1016/j.cell.2023.03.034 ↗
84. 10.1016/j.ymthe.2020.07.02110.1016/j.ymthe.2020.07.021 ↗
85. 10.1182/blood‐2023‐18636510.1182/blood‐2023‐186365 ↗
86. ClinicalTrials.gov, Identifier: NCT06559176
87. D. P.Waterman S.Modi A. Y.Volmar et al. “Prime Editing advancements enable in vivo therapeutic correction of ATP7B p.H1069Q and p.R778L mutations in Wilson's disease ” presented atESGCT 31st Annual Congress European Society of Gene and Cell Therapy Rome Italy October 2024.
88. ClinicalTrials.gov Identifier: NCT07226622 "Prescreening Study to Identify Potential Participants for a Clinical Study in Wilson Disease (WD) Due to the ATP7B p.H1069Q or p.R778L Mutations "https://clinicaltrials.gov/study/NCT07226622 (accessed: December 2025).
89. PrimeMedicine "Pipeline " (2025) https://primemedicine.com/pipeline/#our‐pipeline(accessed: December 2025).
90. 10.1016/S0952‐7915(03)00109‐210.1016/S0952‐7915(03)00109‐2 ↗
91. J.Gori “Development of a Prime Edited CD34+ cell Drug Product for the Treatment of P47phox Chronic Granulomatous Disease ” presented at27th ASGCT Annual Meeting Baltimore MD May 2024.
92. 10.1038/s41572‐018‐0018‐310.1038/s41572‐018‐0018‐3 ↗
93. 10.1038/s41580‐021‐00382‐610.1038/s41580‐021‐00382‐6 ↗
94. A. V.Anzalone “Developing Prime Editors to Treat Repeat Expansion Diseases ” presented atAIChE International Conference on CRISPR Technologies (Houston TX October 2023).
95. 10.1038/s41587‐023‐02078‐y10.1038/s41587‐023‐02078‐y ↗
96. 10.1038/s41551‐025‐01399‐410.1038/s41551‐025‐01399‐4 ↗
97. 10.1089/genbio.2023.004510.1089/genbio.2023.0045 ↗
98. 10.1038/s41578‐021‐00358‐010.1038/s41578‐021‐00358‐0 ↗